Big Science
Publishers
Serving Towards Science
Big Science
Publishers
Serving Towards Science
Big Science
Publishers
Serving Towards Science
ISSN: 3139-4191
Big Science Publishers LLP (registered under section 12(1) of the LLP act 2008) is a fully open access non-annual journal, publish high quality science-based articles. Big Science Publishers also guide the young budding researchers, UG/PG students and scholars and other academic professional who wants to learn the manuscript writing.
Big Science Publishers LLP (registered under section 12(1) of the LLP act 2008) is a fully open access non-annual journal, publish high quality science-based articles. Big Science Publishers also guide the young budding researchers, UG/PG students and scholars and other academic professional who wants to learn the manuscript writing.
Alzheimer's disease (AD), a neurodegenerative disease is a serious challenge in its early diagnosis, long-term treatment, and customized therapeutic regimens. Traditional diagnosis and treatment are largely ineffective in detecting the disease at the preclinical stage or regulating patient uniqueness. The use of Artificial Intelligence (AI) in the care of Alzheimer's patients has the revolutionary potential in each phase of the disease. This article explores how AI-driven technologies drive early detection using high-speed imaging analysis, biomarker analysis, and predictive modeling using machine learning algorithms. AI-driven smartphone applications and wearables also drive medication compliance by providing real-time reminders, intake tracking, and detection of behavioral drifts. AI applies patient data such as genomics, lifestyle, and clinical history to individualize treatment protocols and maximize therapeutic outcomes in personalized therapy. Through ongoing examination of multi-modal data, AI facilitates dynamic treatment optimization and improves clinical decision-making. Interdisciplinary strategy, diagnostic precision and compliance are not only improved but also permit personalized medicine in AD treatment. The article outlines ethical considerations, data protection, and demands for stringent clinical validation to ensure safe deployment. Finally, AI application in Alzheimer's disease has potential to slow down disease progression, reduce caregiver burden, and enhance the quality of life of patients.
Designed and Developed By Kryoni